{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:03:25Z","timestamp":1790687005258,"version":"4.1.0"},"reference-count":25,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respiration"],"published-print":{"date-parts":[[2020]]},"abstract":"<b><i>Background:<\/i><\/b> Joint pain is frequently observed in patients on antituberculous treatment, and pyrazinamide is known to be associated with joint pain in patients receiving antituberculous treatment. Fluoroquinolone-associated joint pain and tendon injury have been reported in long-term corticosteroid and transplant recipients, but data are lacking in patients with tuberculosis. <b><i>Objectives:<\/i><\/b> The objective of this study was to examine the incidence of joint pain manifested during administration of antituberculous therapy and their association with fluoroquinolones. <b><i>Methods:<\/i><\/b> Patients diagnosed with tuberculosis attending the outpatient clinic over a period of 1 year were reviewed and divided into 3 groups: group A receiving pyrazinamide, group B receiving a fluoroquinolone, and group C receiving both pyrazinamide and a fluoroquinolone. Latency to onset of joint pain was noted in all 3 groups. Joint pain was initially managed with analgesics, and associated hyperuricemia was treated with allopurinol\/febuxostat. Causative drugs were stopped in case of intolerable joint pain. <b><i>Results:<\/i><\/b> 260 patients (47% females, aged 38 \u00b1 18 years; mean \u00b1 SD) were included [group A (<i>n<\/i> = 140), group B (<i>n<\/i> = 81), and group C (<i>n<\/i> = 39)]. Overall, 76\/260 (29%) patients developed joint pain: group A \u2013 24\/140 patients (17%), group B \u2013 32\/81 patients (40%), and group C \u2013 20\/39 patients (51%). The median latency to the onset of joint pain was 83 days (interquartile range, IQR 40\u2013167): 55 days (IQR 32\u201366) in group A, 138 days (IQR 74\u2013278) in group B, and 88 days (IQR 34\u2013183) in group C. Hyperuricemia was present in 12\/24 (50%) patients in group A and 11\/20 (55%) patients in group C. Pyrazinamide was stopped in 7\/140 (5%) patients in group A, fluoroquinolones in 6\/81 (7%) patients in group B, and both pyrazinamide and fluoroquinolones were stopped in 5\/39 (13%) patients in group C because of intolerable joint pain. Major joints affected were knees and ankles. <b><i>Conclusion:<\/i><\/b> There is a high incidence of joint pain in patients receiving antituberculous treatment, which is higher when fluoroquinolones or the pyrazinamide-fluoroquinolone combination are administered as compared to pyrazinamide alone.<\/jats:p>","DOI":"10.1159\/000505102","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T22:01:08Z","timestamp":1579039268000},"page":"125-131","source":"Crossref","is-referenced-by-count":2,"title":["High Incidence of New-Onset Joint Pain in Patients on Fluoroquinolones as Antituberculous Treatment"],"prefix":"10.1159","volume":"99","author":[{"given":"Neha\u00a0P.","family":"Mandovra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejashree\u00a0T.","family":"Lele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preyas\u00a0J.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod\u00a0B.","family":"Chavhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u00a0B.","family":"Leuppi-Taegtmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg\u00a0D.","family":"Leuppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant\u00a0N.","family":"Chhajed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.217569"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007482"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1309\/7GBYQTY62PFEHDP1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000297"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.08.004"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00257202"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2012.06.015"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2010.10.003"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0660"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31644-1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2017.04.001"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02308-2016"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(83)90033-8"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7144\/sgf.5.115"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00016.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.10.017"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/194589240501900413"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a816"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120944"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C505"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1558944717701237"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.16.5.458"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0536-17"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410019390"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200326020-00004"}],"container-title":["Respiration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/505102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:17:19Z","timestamp":1745425039000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000505102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,14]]},"published-print":{"date-parts":[[2020,2,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000505102","archive":["Portico"],"relation":{},"ISSN":["0025-7931","1423-0356"],"issn-type":[{"value":"0025-7931","type":"print"},{"value":"1423-0356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}